Tag Archives: Glyscend Therapeutics

Glyscend Initiates Ph2 GLY-200 Obesity Trial; BioAge Raises $170M Series D; Brenzavvy Mark Cuban Cost Plus Drug Company Update

Three cardiometabolic-related news items have been observed: Glyscend Therapeutics initiated a Ph2 trial evaluating its oral BID GLY-200 in obesity (view CT.gov record); BioAge announced the completion of its Series D financing round at $170M led by Sofinnova Investments and participation from Lilly Ventures and Amgen Ventures (view press release); TheracosBio announced it is extending its collaboration with the Mark Cuban Cost Plus Drug Company for Brenzavvy (view press release). Below, FENIX provides highlights and insights into the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Abbott to Acquire Bigfoot; Novo Launches Wegovy in UK; Sernova and Glyscend Appoint New CEOs; SomaLogic Expands Agreement with Novo Through 2025; Novo’s Biocorp Acquisition Updates; Diamyd to Initiate Ph3 DIAGNODE-3 in US

A series of cardiometabolic-related news items have been observed from Abbott, Novo, Sernova, Glyscend, SomaLogic, Biocorp, and Diamyd. Below, FENIX provides highlights and insights for the respective news items. Of note, FENIX will be conducting an in-depth analysis on the Abbott/Bigfoot acquisition in the coming days.

This content is for Read Less members only.
Register

Already a member? Log in here

May 16-19 CHMP Agenda; Glyscend Therapeutics Completes Ph1 GLY-200 Trial in T2DM

Two cardiometabolic-related news items have been observed: The CHMP agenda for this month’s meeting (May 16-19) has been released; and Glyscend Therapeutics announced the completion of its single and multiple ascending dose (SAD/MAD) Ph1 GLY-200 trial in T2DM. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register

Already a member? Log in here